Skip Navigation

Key Eligibility Criteria for CAR T-Cell Therapy for Lymphoma

  • Key eligibility criteria include:

    • Confirmed diagnosis of diffuse large B cell lymphoma (DLBCL), primary mediastinal large B cell lymphoma, or transformed follicular lymphoma to DLBCL that has not responded to first-line chemotherapy, has not responded to second or greater lines of chemotherapy, or has relapsed within 12 months of an autologous stem cell transplant. Therapy must have included a CD20 antibody and an anthracycline.
    • Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures).

    All patients who wish to be evaluated for CAR T-cell therapy must have a referral to DF/BWCC's Adult Lymphoma Program from their oncologist.

  • Caron Jacobson, MD, at a computer

    Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).